Transforming Viral Sequences to A (H1N1) Flu Diagnosis: The Current Status and Future Prospects of rtPCR Based Assays

Authors: Li, Kai; Xiao, Li; Liu, Chunfeng; Zhang, Jia; Sirois, Pierre

Source: Current Pharmaceutical Biotechnology, Volume 11, Number 1, January 2010 , pp. 113-116(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

A variety of technologies can be used in the detection of contagious pathogens. In the early stage of an outbreak of a new infectious disease, rtPCR is advantageous over many other assays. The rtPCR can be developed either using low fidelity DNA polymerase or high fidelity DNA polymerase. The application of high fidelity DNA polymerase allows the shortening of assay development. In addition, the synthesized DNA template used as positive controls is suggested for shortening the time for assay development. Overall comparison of time required for assay development, specificity, and sensitivity for different types of molecular diagnostic technologies, it seems that early confirmation of viral infected patients will be diagnosed primarily with PCR or rtPCR-based assays presently and likely for the near future.

Keywords: A (H1N1); swine flu; rtPCR; sequencing; antibody; molecular diagnosis

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138920110790725339

Publication date: 2010-01-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.